Akero Therapeutics (NASDAQ: AKRO) reported Q2 EPS of ($2.21), $1.85 worse than the analyst estimate of ($0.36).Second Quarter 2019 Financial ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE